HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.
Michael F. Press
Consultant or Advisory Role - GlaxoSmithKline; GlaxoSmithKline; Halozyme Therapeutics ; Halozyme Therapeutics ; Roche; Roche
Honoraria - GlaxoSmithKline; GlaxoSmithKline; Halozyme Therapeutics ; Halozyme Therapeutics ; Roche; Roche
Research Funding - Dendreon; Dendreon; GlaxoSmithKline; GlaxoSmithKline; Roche; Roche
Peter H. O'Donnell
Honoraria - Dendreon
Elizabeth R. Plimack
Honoraria - Dendreon
Leonard G. Gomella
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Research Funding - Dendreon
David I. Quinn
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Padmanee Sharma
Consultant or Advisory Role - Dendreon
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Robert Brownell Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Melissa Chen
Employment or Leadership Position - Dendreon; Dendreon
Dean F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer
Honoraria - Lilly; Lilly
Research Funding - Amgen; Amgen; Amgen; Dendreon; Dendreon; Dendreon; Genentech; Genentech; Genentech; Genta; Novartis; Novartis; Novartis